Open access · US-GOV
via ClinicalTrials.gov Clinical trial
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Authors not listed
Anavex Life Sciences Corp. · 2016
Abstract
This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2016). An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease. <em>Anavex Life Sciences Corp.</em>. https://clinicaltrials.gov/study/NCT02756858
Vancouver
Anonymous. An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease. Anavex Life Sciences Corp.. 2016.
BibTeX
@misc{anon2016AnExte,
title = {An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease},
author = {Anonymous},
journal = {Anavex Life Sciences Corp.},
year = {2016},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
vTv Therapeutics 2016
Open access · US-GOV
Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease
University Hospitals Cleveland Medical Center 2012
Open access · US-GOV
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
H. Lundbeck A/S 2015
Open access · US-GOV
Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
Eli Lilly and Company 2016
Open access · US-GOV
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Shanghai Greenvalley Pharmaceutical Co., Ltd. 2014
Open access · US-GOV